COHEN & STEERS Contact: Brian Meta Senior Vice President Head of Investor Relations and FP&A Tel (212) 796-9353 Financial Highlights | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|-------|------------------------------------|--------------|---------------------------------------|---------|------------------|----------------------| | (in thousands) \nEmployee compensation and benefits | $ | Three \nJune 30, 2024 \n53,097 | Months \n $ | Ende ...

The company will host a conference call on Thursday, July 18, 2024 at 10:00 a.m. (ET) with access available via webcast and telephone. Chief executive officer and president, Joseph Harvey, chief financial officer, Raja Dakkuri, chief investment officer, Jon Cheigh, and executive vice president, Matthew Stadler, will review the company's operating results and outlook and be available for questions. About Cohen & Steers SOURCE Cohen & Steers, Inc. NEW YORK, July 10, 2024 /PRNewswire/ -- Cohen & Steers, Inc. ( ...

| --- | --- | --- | --- | --- | --- | |--------------------------------------------------|----------------|--------|--------------|---------------|-----------| | | | | | | | | ($ in millions) | AUM | Net | Market | | AUM | | By investment vehicle: Institutional Accounts: | 5/31/2024Flows | | Appreciation | Distributions | 6/30/2024 | | Advisory | $18,261 | $29 | $77 | - | $18,367 | | Japan Subadvisory | 8,214 | (43) | 198 | (60) | 8,309 | | Subadvisory excluding Japan | 5,647 | (118) | 17 | - | 5,546 | | To ...

Core Viewpoint - Cohen & Steers Closed-End Funds announced their monthly distributions for July, August, and September 2024, providing specific dividend amounts for each fund [1][2]. Distribution Details - The monthly dividends for the funds are as follows: - Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF): $0.087 - Cohen & Steers Limited Duration Preferred and Income Fund, Inc. (LDP): $0.131 - Cohen & Steers Select Preferred and Income Fund, Inc. (PSF): $0.126 - Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund (PTA): $0.134 - Cohen & Steers Total Return Realty Fund, Inc. (RFI): $0.080 - Cohen & Steers Real Estate Opportunities and Income Fund (RLTY): $0.110 - Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP): $0.136 - Cohen & Steers Quality Income Realty Fund, Inc. (RQI): $0.080 - Cohen & Steers Infrastructure Fund, Inc. (UTF): $0.155 [1][2]. Managed Distribution Policy - The funds have implemented a managed distribution policy, allowing for greater flexibility in realizing long-term capital gains and distributing them regularly to shareholders [2][3]. - The Board of Directors retains the right to amend, terminate, or suspend this policy, which could impact the market price of the funds' shares [2]. Distribution Composition - Distributions may include net investment income, long-term capital gains, short-term capital gains, and/or return of capital, with the possibility of adjustments based on portfolio and market conditions [3][5]. - Return of capital may be taxed as ordinary income under federal tax regulations [3][4]. Reporting and Information - Each fund will issue a press release and notice prior to the payment date of the distribution, detailing the amount and sources of the distribution [5][6]. - Shareholders will receive a Form 1099-DIV for tax reporting purposes at the end of the calendar year [7].

NEW YORK, June 24, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Raja Dakkuri has joined Cohen & Steers as Executive Vice President and Chief Financial Officer. Mr. Dakkuri succeeds Matthew Stadler, who previously notified Cohen & Steers on October 17, 2023 of his intention to retire during 2024 upon the appointment of his successor. Mr. Dakkuri joins Cohen & Steers from Valley National Bancorp and Bank, where he served as Chief Risk Officer. Prior to that he was an executive at ...

Dyne engineered FORCE-GAA by leveraging the FORCE platform and evaluated efficacy in vivo using hTfR1/6Neo mice, that were developed by crossing the well-established 6Neo mouse model of Pompe with mice expressing human transferrin receptor 1. Intravenous administration of FORCE-GAA cleared glycogen in muscle and the CNS and normalized lysosomal size in hTfR1/6Neo mice. FORCE-GAA reduced serum neurofilament light chain, a biomarker of axonal injury, providing evidence of benefit in the CNS. FORCEGAA also dis ...

The new enhancements to the SmartWall ONE Service Portal are designed to drive business growth by positioning security as a cornerstone of value, simplifying the process of showcasing benefits and capitalizing on upselling opportunities. SOURCE Corero Network Security MARLBOROUGH, Mass. and EDINBURGH, United Kingdom, June 20, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced significant enhancements to its ...

Core Insights - The FDA has lifted the partial clinical hold on PTC518 based on positive interim results from the Phase 2 PIVOT-HD study in Huntington's disease patients [1][18] - PTC518 demonstrated dose-dependent lowering of mutant huntingtin (mHTT) protein levels in both blood and cerebrospinal fluid (CSF) after 12 months of treatment [1][2] - The treatment showed a notable slowing in the progression of motor symptoms compared to placebo, with a 2.0 points worsening for the 5mg dose and 1.3 points worsening for the 10mg dose [2] Company Overview - PTC Therapeutics, Inc. is focused on the discovery, development, and commercialization of medicines for rare disorders, leveraging its scientific and clinical expertise [5][20] - The company aims to provide access to best-in-class treatments for patients with limited options, emphasizing its commitment to innovation and a diversified pipeline [5][20] Huntington's Disease Context - Huntington's disease is a hereditary genetic disorder affecting the central nervous system, caused by a defective gene that produces a toxic form of the Huntingtin protein [19] - Currently, there are no approved drugs that can delay the onset or slow the progression of Huntington's disease, highlighting the need for effective therapies like PTC518 [19]

"We are thrilled to continue and deepen our partnership with A2 Hosting," said Carl Herberger, CEO of Corero Network Security. "Their decision to extend their long-term agreement is a testament to the effectiveness of our DDoS protection solutions and our commitment to supporting their business objectives. We look forward to continuing to help A2 Hosting deliver secure and reliable services to their customers." About Corero Network Security SOURCE Corero Network Security MARLBOROUGH, Mass., June 13, 2024 /P ...

MARLBOROUGH, Mass., June 12, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, is pleased to announce that it has won ChannelVision's 2024 Visionary Spotlight Award (VSA) for Cybersecurity (Business Technology) for its market-leading Corero SmartWall ONE™ DDoS protection solution. "We are excited that SmartWall ONE has again been singled out as a best-in-breed anti-DDoS solution," said Carl Herberger, CEO of Corero Networ ...